Literature DB >> 8417942

Cardiac index vs oxygen-derived parameters for rational use of dobutamine in patients with congestive heart failure.

J L Teboul1, L Graini, R Boujdaria, C Berton, C Richard.   

Abstract

In patients with congestive heart failure (CHF), catecholaminergic agents may exert thermogenic effects that limit their beneficial effects in terms of global tissue oxygenation. Oxygen extraction ratio (O2ER) or mixed venous blood saturation (SvO2) might take into account better than cardiac index (CI) the resultant effect of such agents on peripheral oxygenation. We tested this hypothesis in a series of 20 patients with severe CHF and normal blood lactate levels undergoing pulmonary artery catheterization and receiving incremental doses of dobutamine: 0 (Do), 5 (D5), 10 (D10), and 15 micrograms/kg/min (D15). A significant dose-effect relationship (p < 0.01) was found between dose of dobutamine and CI (CI = 0.06 dose + 1.82). By contrast, no dose-effect relationship was observed between dobutamine dose and either O2ER or SvO2. Indeed, a biphasic profile was observed for O2ER and SvO2. From D0 to D10, O2ER decreased (from 45 +/- 6 to 35 +/- 7 percent) and SvO2 increased (from 52 +/- 7 to 62 +/- 7 percent). From D10 to D15, no further change was observed for both parameters. This latter finding was related to a significant increase in VO2 at D15 (p < 0.01). In these normolactatemic patients with unchanged VO2 from D0 to D10 while DO2 linearly increased (from D0 to D15), the increase in VO2 at D15 was probably due to an increase in oxygen demand induced by the drug. Our results suggest that dobutamine at a dose of 15 micrograms/kg/min can induce an increase in O2 demand that might offset the improvement in CI. Thus, in patients with CHF, oxygen-derived parameters such as O2ER and SvO2 should be more appropriate than CI to assess the efficacy of dobutamine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417942     DOI: 10.1378/chest.103.1.81

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Hemodynamic management of cardiovascular failure by using PCO(2) venous-arterial difference.

Authors:  Martin Dres; Xavier Monnet; Jean-Louis Teboul
Journal:  J Clin Monit Comput       Date:  2012-07-25       Impact factor: 2.502

2.  Changes in regional blood flow and pCO(2) gradients during isolated abdominal aortic blood flow reduction.

Authors:  Rafael Knuesel; Stephan M Jakob; Lukas Brander; Hendrik Bracht; Andreas Siegenthaler; Jukka Takala
Journal:  Intensive Care Med       Date:  2003-09-17       Impact factor: 17.440

3.  Time course of central venous-to-arterial carbon dioxide tension difference in septic shock patients receiving incremental doses of dobutamine.

Authors:  Jihad Mallat; Younes Benzidi; Julia Salleron; Malcolm Lemyze; Gaëlle Gasan; Nicolas Vangrunderbeeck; Florent Pepy; Laurent Tronchon; Benoit Vallet; Didier Thevenin
Journal:  Intensive Care Med       Date:  2013-12-05       Impact factor: 17.440

4.  Cardiac resynchronization therapy and AV optimization increase myocardial oxygen consumption, but increase cardiac function more than proportionally.

Authors:  Andreas Kyriacou; Punam A Pabari; Jamil Mayet; Nicholas S Peters; D Wyn Davies; P Boon Lim; David Lefroy; Alun D Hughes; Prapa Kanagaratnam; Darrel P Francis; Zachary I Whinnett
Journal:  Int J Cardiol       Date:  2013-10-16       Impact factor: 4.164

5.  Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial.

Authors:  Lee S Nguyen; Pierre Squara; Julien Amour; Daniel Carbognani; Kamel Bouabdallah; Stéphane Thierry; Caroline Apert-Verneuil; Aurélie Moyne; Bernard Cholley
Journal:  Crit Care       Date:  2018-08-17       Impact factor: 9.097

6.  Perioperative optimization and right heart catheterization: what technique in which patient?

Authors:  Daniel De Backer; Jacques Creteur; Jean-Louis Vincent
Journal:  Crit Care       Date:  2003-03-14       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.